Functional and anatomic consequences of subretinal dosing in the cynomolgus macaque

Archives of Ophthalmology

Volumn 130, Issue 1, 2012, Pages 65-75

  Nork, T Michael ^a,b   Murphy, Christopher J ^a,d   Kim, Charlene B Y ^a,b   Ver Hoeve, James N ^b   Rasmussen, Carol A ^a,b   Miller, Paul E ^b   Wabers, Hugh D ^a,b   Neider, Michael W ^a,b   Dubielzig, Richard R ^a,b   McCulloh, Ryan J ^c   Christian, Brian J ^c  

^a Comparative Ophthalmic Research Laboratories ^*  (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Covance Laboratories Inc ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALANCED SALT SOLUTION; CONE OPSIN; GLIAL FIBRILLARY ACIDIC PROTEIN; RHODOPSIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; ELECTRORETINOGRAPHY; FUNCTIONAL ANATOMY; HAPLORHINI; HISTOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA; SUBRETINAL DRUG ADMINISTRATION; TRANSMISSION ELECTRON MICROSCOPY;

ACETATES; ANIMALS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; ELECTRORETINOGRAPHY; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; INTRAVITREAL INJECTIONS; MACACA FASCICULARIS; MICROSCOPY, ELECTRON; MINERALS; OPHTHALMOSCOPY; OPSINS; RETINA; RHODOPSIN; SODIUM CHLORIDE; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84862917889     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.295     Document Type: Article

References (65)

1. Rosenfeld PJ, Brown DM, Heier JS, et al MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355 (14):1419-1431. (Pubitemid 44511557)
2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.
3. Moreno SF, Paloma JB. Therapeutic anti-VEGF in age-related macular degeneration: ranibizumab and bevacizumab controversy. Br J Ophthalmol. 2008; 92(6):866-867.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27): 2805-2816. (Pubitemid 40051904)
5. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-11398. (Pubitemid 34920936)
6. Vascular endothelial growth factor (VEGF) Trap-Eye: investigation of efficacy and safety in wet age-related macular degeneration (AMD) (VIEW 1). http://clinicaltrials.gov/ct2/show/NCT00509795. Accessed August 1, 2011.
7. Vascular endothelial growth factor (VEGF) Trap-Eye: investigation of efficacy and safety in wet age related macular degeneration (AMD) (VIEW 2). http://clinicaltrials .gov/ct2/show/NCT00637377. Accessed August 1, 2011.
8. Lichtlen P, Lam TT, Nork TM, Streit T, Urech DM. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sci. 2010;51(9):4738-4745.
9. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet. 2001;28(1):92-95. (Pubitemid 32405824)
10. Narfström K, Katz ML, Bragadottir R, et al. Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci. 2003;44(4):1663-1672. (Pubitemid 36378596)
11. Narfström K, Katz ML, Ford M, Redmond TM, Rakoczy E, Bragadóttir R. In vivo gene therapy in young and adult RPE65-/- dogs produces long-term visual improvement. J Hered. 2003;94(1):31-37. (Pubitemid 37553179)
12. Narfström K, Seeliger M, Lai CM, et al. Morphological aspects related to longterm functional improvement of the retina in the 4 years following rAAV-mediated gene transfer in the RPE65 null mutation dog. Adv Exp Med Biol. 2008; 613:139-146.
13. Ford M, Bragadóttir R, Rakoczy PE, Narfström K. Gene transfer in the RPE65 null mutation dog: relationship between construct volume, visual behavior and electroretinographic (ERG) results. Doc Ophthalmol. 2003;107(1):79-86. (Pubitemid 36896241)
14. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther. 2005;12(6):1072-1082. (Pubitemid 41723041)
15. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008;358(21):2231-2239. (Pubitemid 351724452)
16. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adenoassociated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19(10):979-990.
17. Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374(9701):1597-1605.
18. den Hollander AI, Black A, Bennett J, Cremers FP. Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest. 2010;120(9):3042-3053.
19. Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res. 2010;29(5):398-427.
20. Kong J, Kim SR, Binley K, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther. 2008;15(19): 1311-1320.
21. Ikeda Y, Yonemitsu Y, Miyazaki M, et al. Stable retinal gene expression in nonhuman primates via subretinal injection of SIVagm-based lentiviral vectors. Hum Gene Ther. 2009;20(6):573-579.
22. Balaggan KS, Binley K, Esapa M, et al. EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. Gene Ther. 2006;13(15):1153-1165. (Pubitemid 44084074)
23. Balaggan KS, Binley K, Esapa M, et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J Gene Med. 2006;8(3):275-285.
24. Nicoud M, Kong J, Iqball S, et al. Development of photoreceptor-specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors. J Gene Med. 2007;9(12):1015-1023. (Pubitemid 350286406)
25. Kachi S, Binley K, Yokoi K, et al. Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization. Hum Gene Ther. 2009;20(1):31-39.
26. Lund RD, Wang SM, Klimanskaya I, et al. Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats. Cloning Stem Cells. 2006; 8(3):189-199. (Pubitemid 44735173)
27. Gamm DM, Wang SM, Lu B, et al. Protection of visual functions by human neural progenitors in a rat model of retinal disease. PLoS One. 2007;2(3):e338.
28. Lund RD, Wang SM, Lu B, et al. Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. Stem Cells. 2007;25(3):602-611. (Pubitemid 46354218)
29. Wang SM, Girman S, Lu B, et al. Long-term vision rescue by human neural progenitors in a rat model of photoreceptor degeneration. Invest Ophthalmol Vis Sci. 2008;49(7):3201-3206.
30. Lu B, Malcuit C, Wang S, et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells. 2009;27(9):2126-2135.
31. Wadman M. FDA approves third human stem cell trial. Nature. 2011;469:137.
32. Conley SM, Naash MI. Nanoparticles for retinal gene therapy. Prog Retin Eye Res. 2010;29(5):376-397.
33. Komáromy AM, Alexander JJ, Cooper AE, et al. Targeting gene expression to cones with human cone opsin promoters in recombinant AAV [published correction appears in Gene Ther. 2008;15(14):1073]. Gene Ther. 2008;15(14):1049-1055. (Pubitemid 351927695)
34. Komáromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010;19(13):2581-2593.
35. Mancuso K, Hauswirth WW, Li Q, et al. Gene therapy for red-green colour blindness in adult primates. Nature. 2009;461(7265):784-787.
36. Kim CBY, Ver Hoeve JN, Kaufman PL, Nork TM. Interspecies and gender differences in multifocal electroretinograms of cynomolgus and rhesus macaques. Doc Ophthalmol. 2004;109(1):73-86. (Pubitemid 40012056)
37. Mayor HD, Hampton JC, Rosario B. A simple method for removing the resin from epoxy-embedded tissue. J Biophys Biochem Cytol. 1961;9:909-910.
38. Guérin CJ, Anderson DH, Fariss RN, Fisher SK. Retinal reattachment of the primate macula: photoreceptor recovery after short-term detachment. Invest Ophthalmol Vis Sci. 1989;30(8):1708-1725. (Pubitemid 19214991)
39. Guérin CJ, Anderson DH, Fisher SK. Changes in intermediate filament immunolabeling occur in response to retinal detachment and reattachment in primates. Invest Ophthalmol Vis Sci. 1990;31(8):1474-1482. (Pubitemid 20265952)
40. Guérin CJ, Lewis GP, Fisher SK, Anderson DH. Recovery of photoreceptor outer segment length and analysis of membrane assembly rates in regenerating primate photoreceptor outer segments. Invest Ophthalmol Vis Sci. 1993;34(1): 175-183. (Pubitemid 23045115)
41. Kim CBY, VerHoeve JN, Kaufman PL, Nork TM. Effects of reference electrode location on monopolar-derived multifocal electroretinograms in cynomolgus monkeys. Doc Ophthalmol. 2005;111(2):113-125. (Pubitemid 43337115)
42. Nork TM, Kim CBY, Heatley GA, et al. Serial multifocal electroretinograms during long-term elevation and reduction of intraocular pressure in non-human primates. Doc Ophthalmol. 2010;120(3):273-289.
43. Schatz P, Holm K, Andréasson S. Retinal function after scleral buckling for recent onset rhegmatogenous retinal detachment: assessment with electroretinography and optical coherence tomography. Retina. 2007;27(1):30-36. (Pubitemid 46095827)
44. Hood DC, Frishman LJ, Saszik S, Viswanathan S. Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol Vis Sci. 2002;43(5):1673-1685. (Pubitemid 34462674)
45. Sasoh M, Yoshida S, Kuze M, Uji Y. The multifocal electroretinogram in retinal detachment. Doc Ophthalmol. 1997-1998;94(3):239-252. (Pubitemid 28294895)
46. Chisholm IA, McClure E, Foulds WS. Functional recovery of the retina after retinal detachment. Trans Ophthalmol Soc U K. 1975;95(1):167-172.
47. Faude F, Francke M, Makarov F, et al. Experimental retinal detachment causes widespread and multilayered degeneration in rabbit retina. J Neurocytol. 2001; 30(5):379-390.
48. Kyhn MV, Kiilgaard JF, Lopez AG, Scherfig E, Prause JU, la Cour M. Functional implications of short-term retinal detachment in porcine eyes: study by multifocal electroretinography. Acta Ophthalmol. 2008;86(1):18-25. (Pubitemid 351512465)
49. Brinton DA, Wilkinson CP, Hilton GF; American Academy of Ophthalmology. Retinal Detachment: Principles and Practice. 3rd ed. Oxford, England: Oxford University Press; 2009.
50. Widdowson P, Ellis S, Nork TM, et al. Ocular tolerance of an EIAV based lentiviral vector treatment for neovascular age-related macular degeneration (RetinoStat ®) in rabbit and nonhuman primate models. Presented at: 2010 ARVO Annual Meeting; May 4, 2010; Fort. Lauderdale, FL. Abstract 3104.
51. Marmor MF, Yao XY, Hageman GS. Retinal adhesiveness in surgically enucleated human eyes. Retina. 1994;14(2):181-186. (Pubitemid 24195750)
52. Szurman P, Roters S, Grisanti S, et al. Ultrastructural changes after artificial retinal detachment with modified retinal adhesion. Invest Ophthalmol Vis Sci. 2006; 47(11):4983-4989. (Pubitemid 46586403)
53. Tanihara H, Hangai M, Sawaguchi S, et al. Up-regulation of glial fibrillary acidic protein in the retina of primate eyes with experimental glaucoma. Arch Ophthalmol. 1997;115(6):752-756. (Pubitemid 27276258)
54. Grosche J, Härtig W, Reichenbach A. Expression of glial fibrillary acidic protein (GFAP), glutamine synthetase (GS), and Bcl-2 protooncogene protein by Müller (glial) cells in retinal light damage of rats. Neurosci Lett. 1995;185(2):119-122.
55. Osborne NN, Block F, Sontag KH. Reduction of ocular blood flow results in glial fibrillary acidic protein (GFAP) expression in rat retinal Müller cells. Vis Neurosci. 1991;7(6):637-639.
56. Erickson PA, Fisher SK, Guérin CJ, Anderson DH, Kaska DD. Glial fibrillary acidic protein increases in Müller cells after retinal detachment. Exp Eye Res. 1987; 44(1):37-48. (Pubitemid 17024026)
57. Lewis GP, Guérin CJ, Anderson DH, Matsumoto B, Fisher SK. Rapid changes in the expression of glial cell proteins caused by experimental retinal detachment. Am J Ophthalmol. 1994;118(3):368-376. (Pubitemid 24281731)
58. Lewis GP, Charteris DG, Sethi CS, Leitner WP, Linberg KA, Fisher SK. The ability of rapid retinal reattachment to stop or reverse the cellular and molecular events initiated by detachment. Invest Ophthalmol Vis Sci. 2002;43(7):2412-2420. (Pubitemid 34700676)
59. Lewis GP, Charteris DG, Sethi CS, Fisher SK. Animal models of retinal detachment and reattachment: identifying cellular events that may affect visual recovery. Eye (Lond). 2002;16(4):375-387. (Pubitemid 34845965)
60. Schocket LS, Witkin AJ, Fujimoto JG, et al. Ultrahigh-resolution optical coherence tomography in patients with decreased visual acuity after retinal detachment repair. Ophthalmology. 2006;113(4):666-672.
61. Smith AJ, Telander DG, Zawadzki RJ, et al. High-resolution Fourier-domain optical coherence tomography and microperimetric findings after macula-off retinal detachment repair. Ophthalmology. 2008;115(11):1923-1929.
62. Wakabayashi T, Oshima Y, Fujimoto H, et al. Foveal microstructure and visual acuity after retinal detachment repair: imaging analysis by Fourier-domain optical coherence tomography. Ophthalmology. 2009;116(3):519-528.
63. Ross WH, Stockl FA. Visual recovery after retinal detachment. Curr Opin Ophthalmol. 2000;11(3):191-194. (Pubitemid 30341565)
64. Wolfensberger TJ, Gonvers M. Optical coherence tomography in the evaluation of incomplete visual acuity recovery after macula-off retinal detachments. Graefes Arch Clin Exp Ophthalmol. 2002;240(2):85-89. (Pubitemid 36075579)
65. Abouzeid H, Becker K, Holz FG, Wolfensberger TJ. Submacular fluid after encircling buckle surgery for inferior macula-off retinal detachment in young patients. Acta Ophthalmol. 2009;87(1):96-99.